Cancer Genetics

Scope & Guideline

Bridging Genetics and Cancer for a Healthier Tomorrow

Introduction

Explore the comprehensive scope of Cancer Genetics through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Cancer Genetics in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN2210-7762
PublisherELSEVIER SCIENCE INC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 2011 to 2024
AbbreviationCANCER GENET-NY / Cancer Genet.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressSTE 800, 230 PARK AVE, NEW YORK, NY 10169

Aims and Scopes

The journal 'Cancer Genetics' focuses on the intersection of genetic research and cancer biology, providing a platform for the dissemination of findings that enhance our understanding of cancer genetics and its implications for diagnosis, treatment, and patient management.
  1. Genetic Mechanisms of Cancer:
    The journal emphasizes studies that elucidate the genetic alterations associated with various cancers, including mutations, copy number variations, and chromosomal rearrangements.
  2. Clinical Applications of Genetic Testing:
    Research published in the journal often explores the application of genetic testing for cancer risk assessment, diagnosis, and treatment decisions, including the use of targeted therapies and personalized medicine.
  3. Biomarker Discovery and Validation:
    The journal highlights the identification and validation of genetic and epigenetic biomarkers that can predict cancer progression, treatment response, and patient outcomes.
  4. Molecular Pathology and Tumor Genomics:
    A significant focus is placed on the integration of molecular pathology techniques with genomic sequencing to improve the understanding of tumor heterogeneity and therapeutic resistance.
  5. Translational Research and Therapeutics:
    The journal supports translational research that bridges laboratory findings with clinical practice, particularly studies that investigate novel therapeutic strategies and drug development.
The journal 'Cancer Genetics' has adapted to the evolving landscape of cancer research, with several themes emerging as prominent areas of interest in recent publications.
  1. Liquid Biopsies and ctDNA:
    There is a growing emphasis on the use of liquid biopsies and circulating tumor DNA (ctDNA) as non-invasive tools for cancer detection, monitoring treatment response, and predicting relapse.
  2. Genetic Profiling and Personalized Medicine:
    Research focusing on comprehensive genetic profiling of tumors to inform personalized treatment strategies is on the rise, highlighting the shift towards tailored therapies based on individual genetic makeup.
  3. Functional Genomics and Gene Editing:
    Emerging methodologies such as CRISPR and other gene editing technologies are increasingly featured, showcasing their potential in understanding cancer biology and developing novel therapeutic approaches.
  4. Long Non-Coding RNAs and Epigenetic Regulation:
    The investigation of long non-coding RNAs and their role in cancer development and progression is gaining traction, reflecting a broader interest in epigenetic factors that influence gene expression in malignancies.
  5. Integration of Multi-Omics Data:
    There is a trend towards the integration of multi-omics approaches (genomics, transcriptomics, proteomics) to provide a more comprehensive understanding of cancer biology and treatment responses.

Declining or Waning

While 'Cancer Genetics' has seen significant advancements in various areas of cancer research, certain themes have begun to decline in prominence over recent years, indicating a shift in research focus and interest.
  1. Traditional Cytogenetics:
    Research centered around traditional cytogenetic techniques such as karyotyping is appearing less frequently, as newer genomic technologies like next-generation sequencing (NGS) become more prevalent.
  2. General Cancer Epidemiology:
    There is a noticeable decline in studies focusing solely on cancer epidemiology without a genetic component, as the field increasingly prioritizes genetic and molecular factors in cancer research.
  3. Basic Laboratory Research:
    Papers focusing solely on basic laboratory techniques without direct applications to clinical practice or genetic implications are becoming less common, as the journal pivots toward more clinically relevant research.
  4. Single Gene Studies:
    Studies investigating the role of single genes in cancer without considering the broader context of genomic interactions and networks are waning, reflecting a trend towards more integrative genomic approaches.

Similar Journals

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS

Connecting Research to Real-World Implications
Publisher: ELSEVIERISSN: 1386-1964Frequency: 12 issues/year

MUTATION RESEARCH - FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS is a premier peer-reviewed journal published by Elsevier, dedicated to advancing the understanding of mutagenesis and its broader implications in genetics, health, and molecular biology. With an impressive converged publication history from 1964 to 2024, this journal provides a vital platform for the dissemination of high-quality research findings, contributing significantly to the field's knowledge base. Indexed in Scopus, it holds a Category Quartile ranking of Q3 in Genetics and Q2 in Health, Toxicology, and Mutagenesis, further underscoring its relevance and stature. Access options are available, catering to a diverse audience of researchers, professionals, and students eager to stay informed on the latest developments in mutagenesis research. By bridging experimental studies and theoretical frameworks, the journal plays a crucial role in exploring the fundamental mechanisms underlying genetic mutations and their effects on human health and the environment.

Gene Reports

Shaping the Future of Genetic Research
Publisher: ELSEVIERISSN: Frequency: 4 issues/year

Gene Reports is a prominent academic journal published by Elsevier that focuses on the rapidly evolving field of genetics. Launched in 2015, this journal serves as a pivotal platform for the dissemination of cutting-edge research, bridging the gap between basic and applied genetics studies. Although it currently holds a Q4 ranking in the Genetics category and stands at the 248th position out of 347 in Scopus rankings, its potential for growth is significant given the increasing interest in genetic research across various disciplines. With an E-ISSN of 2452-0144, Gene Reports aims to provide open access to original research articles, reviews, and short communications that advance the collective understanding of genetic mechanisms and their applications. As a publication that continues to shape the future of genetics, it is an essential resource for researchers, professionals, and students seeking to stay informed about the latest developments in this crucial field.

CANCER AND METASTASIS REVIEWS

Exploring the Complexities of Cancer Progression
Publisher: SPRINGERISSN: 0167-7659Frequency: 4 issues/year

Cancer and Metastasis Reviews, published by Springer, is a leading journal in the field of oncology and cancer research. With an impressive impact factor placing it in the Q1 category for both Cancer Research and Oncology as of 2023, this journal is ranked 29th out of 404 in Medicine, Oncology, and 22nd out of 230 in Biochemistry, Genetics, and Molecular Biology, reflecting its significant influence and prestige in the academic community. Established in 1982, the journal covers a wide spectrum of topics related to the mechanisms of cancer progression and metastasis, making it an essential resource for researchers, healthcare professionals, and students dedicated to understanding and tackling cancer. Although the journal does not provide open access options, the impactful research it publishes contributes to advances in therapeutic strategies and enhances the collective knowledge surrounding cancer pathophysiology. With research converging from 1982 to 2024, Cancer and Metastasis Reviews continues to be a vital platform for disseminating high-quality scientific information in the ever-evolving landscape of cancer research.

CYTOGENETIC AND GENOME RESEARCH

Connecting researchers to the latest breakthroughs in genetics.
Publisher: KARGERISSN: 1424-8581Frequency: 12 issues/year

CYTOGENETIC AND GENOME RESEARCH is a pivotal journal dedicated to the exploration of cytogenetics, genomics, and their applications within clinical genetics and molecular biology. Published by KARGER in Switzerland, this journal aims to foster comprehensive discussions and disseminate impactful research from diverse fields related to genetics. It operates under an open access model, ensuring that researchers, professionals, and students can easily access and contribute to the latest findings. With coverage spanning from 1962 to 2024, CYTOGENETIC AND GENOME RESEARCH continues to serve as a vital resource, despite its current categorization in the Q4 quartile across Genetics and Molecular Biology. It provides an avenue for advancing the understanding of genomic mechanisms and their implications for human health. The journal encourages submissions that delve into cutting-edge methodologies, data interpretation, and theoretical frameworks, thereby playing a crucial role in the advancement of genetic research and its clinical applications.

HUMAN GENETICS

Driving innovation in clinical genetics.
Publisher: SPRINGERISSN: 0340-6717Frequency: 12 issues/year

HUMAN GENETICS, published by SPRINGER, stands as a cornerstone journal in the field of genetics, offering a wealth of research insights since its inception in 1964. Hailing from Germany, this esteemed journal boasts an impressive Q1 ranking in both Genetics and Clinical Genetics, marking it among the top quartile of journals in these categories for 2023. With a notable Scopus rank of #7 in Clinical Genetics and a percentile ranking of 93, HUMAN GENETICS attracts significant attention from researchers and professionals dedicated to advancing our understanding of genetic influences on human health and disease. Although it does not currently offer Open Access options, the journal provides a critical platform for scholarly communication, aimed at disseminating groundbreaking findings in genetics and biotechnology. As the field evolves, HUMAN GENETICS continues to play an instrumental role in bridging the gap between laboratory research and clinical application, making it an essential resource for students and seasoned researchers alike.

JCO Precision Oncology

Pioneering the Future of Cancer Care with Precision
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: Frequency: 1 issue/year

JCO Precision Oncology, published by Lippincott Williams & Wilkins, is a leading journal in the field of cancer research and oncology, recognized for its high-impact contributions and innovative approaches to precision medicine. Since its inception in 2017, this journal has consistently ranked in the Q1 category in both Cancer Research and Oncology for 2023, reflecting its esteemed position within the academic community. With a rigorous peer-review process and a focus on disseminating cutting-edge research, JCO Precision Oncology serves as a vital platform for researchers, clinicians, and healthcare professionals aiming to enhance the understanding and treatment of cancer through individualized therapies. The journal's comprehensive scope includes studies on genetic profiling, biomarker research, and novel therapeutic strategies, making it an essential resource for anyone involved in cancer care and research. Explore further and join a community committed to advancing precision oncology and improving patient outcomes.

Oncogenesis

Empowering researchers with open access to vital findings.
Publisher: SPRINGERNATUREISSN: 2157-9024Frequency: 1 issue/year

Oncogenesis is a prestigious open access journal, published by SpringerNature, dedicated to advancing our understanding of cancer biology and molecular mechanisms of oncogenesis. Since its inception in 2012, this journal has quickly established itself as a leading platform for innovative research, being ranked in the Q1 quartile in both Cancer Research and Molecular Biology categories for 2023. With an admirable impact factor that reflects its exceptional quality, Oncogenesis is indexed in Scopus, holding notable rankings in both Molecular Biology and Cancer Research, placing in the 87th and 83rd percentile respectively. The journal not only facilitates the dissemination of groundbreaking research but also encourages collaboration among scientists and healthcare professionals across the globe. By offering open access to its articles, Oncogenesis ensures that vital findings reach a diverse audience, fostering a deeper dialogue and understanding in the fight against cancer. Based in the United States but with a global reach, the journal remains committed to publishing high-impact studies that contribute to the advancement of knowledge in the realms of oncology, biochemistry, and genetics.

Lung Cancer-Targets and Therapy

Exploring Innovative Therapies for Lung Cancer
Publisher: DOVE MEDICAL PRESS LTDISSN: Frequency: 1 issue/year

Lung Cancer - Targets and Therapy, published by Dove Medical Press Ltd, serves as a pivotal Open Access journal dedicated to advancing knowledge and research in the field of oncology, specifically focusing on lung cancer. Since its inception in 2010, this journal has provided a platform for disseminating high-quality research articles, reviews, and clinical studies, thereby enhancing the understanding of lung cancer mechanisms, therapies, and clinical outcomes. Currently ranked in the Q2 quartile within the oncology category and positioned at rank #80 out of 404 in Scopus, it resides in the 80th percentile of its field, reflecting its significant impact and relevance. With a commitment to promoting innovative therapies and strategies, Lung Cancer - Targets and Therapy is an essential resource for researchers, healthcare professionals, and students eager to contribute to the evolving landscape of cancer treatment and research.

CANCER SCIENCE

Advancing oncology research for a healthier tomorrow.
Publisher: WILEYISSN: 1347-9032Frequency: 12 issues/year

Cancer Science, an esteemed journal published by Wiley, stands at the forefront of oncology research, boasting an impressive impact factor and a classification in the Q1 category for its contributions in Cancer Research, Medicine, and Oncology as of 2023. Since its inception in 2003 and transitioning to an Open Access model in 2014, the journal has facilitated global dissemination of critical research findings, ensuring that vital information remains accessible to researchers, clinicians, and students alike. With its comprehensive scope covering cutting-edge discoveries in cancer biochemistry, genetics, and molecular biology, Cancer Science is recognized for its rigorous peer-review process and significant contributions to advancing our understanding of cancer. The journal, located at 111 River St, Hoboken, NJ, is an essential resource for anyone dedicated to improving treatment outcomes and pushing the boundaries of cancer research.

JOURNAL OF GENE MEDICINE

Advancing the Frontiers of Gene Therapy
Publisher: WILEYISSN: 1099-498XFrequency: 12 issues/year

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.